71P A phase I study of binimetinib, a MEK inhibitor, in combination with pembrolizumab in patients with advanced non-small cell lung cancer (NCT03991819)

This article has no abstract
Epistemonikos ID: 36652f73e5665b70ce075a169ad58337df0f1dcb
First added on: Feb 17, 2025